Lipfendra Approval Introduces the First Oral PCSK9
Quick Facts
What Is Lipfendra and Who Is It Approved For?
Lipfendra contains enlicitide, a macrocyclic peptide formulated as a once-daily tablet. The FDA approved it for use alongside diet and exercise in adults with high LDL cholesterol, including people with heterozygous familial hypercholesterolemia, an inherited disorder that can cause markedly elevated cholesterol from an early age.
The approval creates an oral alternative within a drug class previously represented by injectable therapies. It may be considered when patients need additional LDL lowering, but treatment decisions should still reflect cardiovascular risk, current cholesterol levels, other medications and the amount of benefit achieved with statins or alternative lipid-lowering therapies.
How Does an Oral PCSK9 Inhibitor Lower LDL Cholesterol?
LDL receptors on liver cells capture circulating LDL particles and help clear them from the blood. PCSK9 binds to these receptors and promotes their degradation. By interrupting that interaction, enlicitide allows more receptors to return to the liver-cell surface, increasing the removal of LDL cholesterol.
Injectable monoclonal antibodies and other therapies already target the PCSK9 pathway, but enlicitide is the first inhibitor of this pathway approved as a tablet. Oral administration could make PCSK9-directed treatment more acceptable to some patients, although adherence remains essential because the medicine must be taken every day.
What Did the Lipfendra Clinical Trials Find?
The FDA based its decision on two randomized, double-blind, placebo-controlled trials enrolling 3,207 adults with severe hypercholesterolemia. In a trial involving adults with atherosclerotic cardiovascular disease or elevated cardiovascular risk, LDL cholesterol fell by approximately 56% at week 24. A separate trial in adults with heterozygous familial hypercholesterolemia found an approximately 59% reduction.
Overall adverse-reaction and treatment-discontinuation rates were similar between enlicitide and placebo in the broader trial. Diarrhea and dizziness occurred more frequently than placebo in the familial hypercholesterolemia trial. The studies primarily established cholesterol lowering; patients should not assume that the reported LDL reductions directly represent an equivalent reduction in heart attacks or strokes.
Frequently Asked Questions
Not automatically. The pivotal trials evaluated enlicitide in adults already receiving maximally tolerated statin therapy. A clinician should determine whether it is an appropriate addition or alternative based on LDL levels, cardiovascular risk and medication tolerance.
It targets the same PCSK9 pathway but is a distinct medicine taken as a once-daily tablet. Previously approved PCSK9-directed treatments have generally been administered by injection.
Lowering LDL cholesterol is an established part of cardiovascular risk reduction, but the FDA trials summarized for this approval primarily measured changes in LDL cholesterol. The reported percentage reductions should not be interpreted as identical reductions in cardiovascular events.
References
- U.S. Food and Drug Administration. FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol. July 2026.
- ClinicalTrials.gov. CORALreef Lipids: A Study of Enlicitide Decanoate in Adults With Hypercholesterolemia (NCT05952856).
- ClinicalTrials.gov. CORALreef HeFH: A Study of Enlicitide Decanoate in Adults With Heterozygous Familial Hypercholesterolemia (NCT05952869).
- Reuters. Merck gets US FDA nod for first-in-its-class oral cholesterol drug. July 2026.